[Update of combined therapies with docetaxel for hormone-independent prostate cancer].
Hormone-independent prostate cancer (HIPC) is the end stage of prostate cancer, with a short median survival of 9-18 months for the patients. Two large phase III studies have demonstrated a survival advantage of docetaxel chemotherapy in HIPC patients. New combined protocols have been developed with promising results. These protocols propose a combination with docetaxel, chemotherapy, antiangiogenic agents, vaccine and biological drugs. This review focuses the progress achieved the combined therapies for HIPC.
Li
Tian-Qing
TQ
Department of Urology, Yunnan Urology Research Laboratory, the Second Hospital Affiliated to Kunming Medical College, Kunming, Yunnan 650101, China. libing7929@sina.com
Wang
Jian-Song
JS
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000627:therapeutic use*; D014612:Vaccines / Q000627:therapeutic use
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D001688:Biological Products; D043823:Taxoids; D014612:Vaccines; D000077143:Docetaxel